Date of publication and mention of the grant of the patent: 22.08.2001 Bulletin 2001/34

Application number: 93304733.4

Date of filing: 17.06.1993

Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates
Verfahren zur Synthese von Zwischenprodukten von-4-Hydroxy-5-halopyrrolo (2,3-d) Pyrimidin
Procédé de synthèse de intermédiaires de la 4-hydroxy-5-halopyrrolo (2,3-d) pyrimidine

Designated Contracting States: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

Priority: 22.06.1992 US 902116

Date of publication of application: 29.12.1993 Bulletin 1993/52

Proprietor: ELI LILLY AND COMPANY Indianapolis, Indiana 46285 (US)

Inventors:
• Barnett, Charles Jackson Indianapolis, Indiana 46240 (US)
• Kobierski, Michael Edward Greenwood, Indiana 46142 (US)

Representative: Hudson, Christopher Mark et al Lilly Industries Limited European Patent Operations Erl Wood Manor Windlesham Surrey GU20 6PH (GB)

References cited:
• TETRAHEDRON LETTERS. vol. 29, no. 33, 1988 , OXFORD GB pages 4061 - 4064 ANTHONY J. COCUZZA ET AL 'Total synthesis of 7-Iodo-2',3'-dideoxy-7-deazapurine nucleosides, key intermediates in the preparation of reagents for the automated sequencing of dna'
• JOURNAL OF HETEROCYCLIC CHEMISTRY. vol. 6, no. 2, April 1969, PROVO US pages 207 - 213 JOHN F. GERSTER ET AL 'A study of electrophilic substitution in the pyrrolo[2,3-d]pyrimidine ring'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
**Description**

[0001] This invention relates to the fields of pharmaceutical and organic chemistry, and provides processes for the synthesis of 4-hydroxy-5-halopyrrolo[2,3-d]pyrimidines which are useful, inter alia, as intermediates in the synthesis of a series of complex antimitabolites of the antifolate type.

[0002] Antimetabolites have been used for a number of years as chemotherapeutic agents in the treatment of cancer. One such drug, methotrexate, is now one of the most widely used anticancer drugs; and many other compounds in the folic acid family have been synthesized, tested and discussed in the chemical and medical literature. The compounds have various activities at the enzymatic level; they inhibit such enzymes as dihydrofolate reductase, folate polyglutamate synthetase, glycaminide ribonucleotide formyltransferase and thymidylate synthetase.

[0003] More recently, a series of 4-hydroxypyrrolo[2,3-d]pyrimidine-L-glutamic acid derivatives have been disclosed and shown to be particularly useful antifolate drugs. See, for example, U.S. Patents 4,996,206; 5,028,608; 5,106,974; and 4,997,838. In the synthesis of these compounds, an important group of intermediates, 4-hydroxy-5-halo-pyrrolo[2,3-d]pyrimidine derivatives, are frequently synthesized and then reacted with the desired carboxylic acid derivative or L-glutamic acid derivative via conventional techniques.

[0004] However, the preparation of 4-hydroxy-5-halo-pyrrolo[2,3-d]pyrimidines by direct halogenation at the C-5 position of the corresponding 4-hydroxypyrrolo[2,3-d]pyrimidines has not been synthetically useful either because of poor regioselectivity, where halogenation frequently occurs at both the C-5 and C-6 positions, or because of the inconvenience of harsh, multi-step processes. See, for example, Cocuzza, A. J., *Tetrahedron* Letters, 29: 4061-4064 (1988); Gerster, et al., J. Het. Chem. 207-213 (1969); and U.S. pat. No. 4,996,206. The present invention provides an improved process for direct halogenation of 4-hydroxypyrrolo[2,3-d]pyrimidines at the C-5 position.

[0005] The resulting compounds, 4-hydroxy-5-halo-pyrrolo[2,3-d]pyrimidines, are primarily useful as intermediates for the synthesis of antineoplastic glutamic acid derivatives. However, one of ordinary skill in the organic chemical arts will recognize that the usefulness of the intermediates synthesized by the processes of this invention is not limited to the synthesis of the above-described antineoplastic agents.

[0006] The present invention provides a method for preparing 4-hydroxy-5-halopyrrolo[2,3-d]pyrimidines of formula I:

![Chemical Structure](image)

wherein

R is H, C1-C4 alkyl, C1-C4 alkoxy, benzyl, an aryl substituent which is unsubstituted or substituted and selected from phenyl, thienyl, pyridyl or furyl, or a substituent of the formula R1-NH-;

R1 is an amino protecting group; and

X is bromo, chloro or iodo, which comprises

(a) reacting a silylating agent with a 4-hydroxypyrrolo[2,3-d]pyrimidine of formula II

![Chemical Structure](image)

wherein

R is as defined above, in the presence of an inert organic solvent; and

(b) iodinating, brominating or chlorinating the reaction product from step (a).
The present invention pertains to processes for the synthesis of 4-hydroxy-5-halopyrrolo[2,3-d]intermediates which are useful, inter alia, as intermediates in the synthesis of a series of complex antimetabolites of the antifolate type.

The compounds of formula I and II exist in tautomeric equilibrium with the corresponding 4(3H)-oxo compounds. For illustrative purposes, the equilibrium for formula II is shown below, in addition to the pyrrolo[2,3-d]pyrimidine ring system which is numbered as follows:

For convenience, the 4-hydroxy form is depicted for formulas I and II, and the corresponding nomenclature is used throughout this specification. However, it is understood that such depictions include the corresponding tautomeric 4(3H)-oxo forms.

The following definitions refer to the various terms used above and throughout the disclosure.

The term "halo" refers to bromo, chloro, fluoro and iodo.

The term "C1-C4 alkyl" refers to the straight or branched aliphatic chains of 1-4 carbon atoms, including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

The term "C1-C4 alkoxy" represents an alkyl group of 1 to 4 carbon atoms attached through an oxygen bridge such as methoxy, ethoxy, n-propoxy, isopropoxy, and the like.

The term "aryl" denotes an unsubstituted or substituted aromatic residue derived by the removal of a hydrogen atom from an aromatic hydrocarbon, such as, for example, phenyl, thiophenyl, pyridyl or furyl. The aromatic residues are unsubstituted or substituted with 1, 2 or 3 substituents independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy.

The amino protecting group designated R1 in formulas I and II, and as utilized herein, denotes a group which generally is not found in a final therapeutic compound, but which is intentionally introduced during a portion of the synthetic process to protect an amino group which may otherwise react in the course of chemical manipulations, and is then removed at a late stage of the synthesis. Numerous reactions for the formation and removal of such a protecting group are described in a number of standard works including, for example, "Protective Groups in Organic Chemistry", Plenum Press, (London and New York, 1973); Greene, Th. W., "Protecting Groups in Organic Synthesis", Wiley, (New York, 1981); and "The Peptides", Vol. I, Schroöder and Lubke, Academic Press, (London and New York, 1965).

Typically, an amide utilizing an acyl group which is selectively removable under mild conditions, such as for example, formyl, acetyl, propionyl, butyryl or furyl acetyl, is useful. A tertiary alkanoyl such as 2,2-dimethylpropionyl is especially useful. Other amino protecting groups include N-alkoxycarbonyls such as N-methoxycarbonyl, N-ethoxycarbonyl, N-(t-butyloxycarbonyl) and N-diisopropyl-methoxycarbonyl.

The term "lower alkanoyl group of from 1 to 8 carbon atoms" refers to straight or branched univalent aliphatic acyl groups of 1-8 carbon atoms including, for example, formyl, acetyl, propionyl, butyryl, α-methylpropionyl, valeryl, α-methylbutyryl, β-methylbutyryl, pivaloyl, octanoyl, and the like.

Formula II compounds are prepared by methods commonly known to organic chemists. For example, Davoll, J. (J. Chem. Soc., 131 (1960)) describes the synthesis of 4-hydroxypyrrolo[2,3-d]pyrimidine. In addition, the synthesis of 2-methyl-, 2-ethyl-, n-propyl- and 2-phenyl-4-hydroxy-pyrrolo[2,3-d]pyrimidines is described by West, R.A., et al., J. Org. Chem., 26: 3809-3812 (1961). Alternatively, the 2-position of the pyrrolo[2,3-d]pyrimidine ring can carry other aryl groups such as thiophenyl, pyridyl and furyl. In addition to phenyl, each of these aryl groups may be substituted by conventional means known in the art with 1, 2 or 3 substituents independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy.

Preferred formula II compounds include unsubstituted 4-hydroxypyrrolo[2,3-d]pyrimidine and 2-methyl-, 2-ethyl-, 2-methoxy- and 2-phenyl-4-hydroxy-pyrrolo[2,3-d]pyrimidines.

Other preferred formula II compounds include 2-protected-amino-4-hydroxy-pyrrolo[2,3-d]pyrimidines. Example 1, infra, describes the preferred method for the synthesis of 2-amino-4-hydroxy-pyrrolo[2,3-d]pyrimidines while Example 2, infra, describes a representative method for protecting the 2-amino-substituent. Although amino protecting groups generally are known in the art would adequately protect the 2-amino-substituent of formula II, an unsubstituted or substituted lower alkanoyl group of 1-8 carbon atoms is preferred. Of these, 2,2-dimethylpropionyl is especially preferred.
The process of this invention is carried out by (a) reacting a silylating agent with a 4-hydroxypyrrolo[2,3-d]pyrimidine of formula II, in the presence of an inert solvent; and (b) iodinating or brominating the resulting product from step (a). This process may be carried out as two independent processes or, preferably, carried out, in situ, as a single process where step (b) is conducted immediately following the completion of step (a).

In step (a), generally known silylating agents are employed. See, for example, Calvin, E.W., "Silicon Reagents in Organic Synthesis", Academic Press, (London, et al., 1988) which is herein incorporated by reference. Particularly useful silylating agents include "tri-lower alkyl silyl" agents, the term of which contemplates triisopropylsilyl, tri-methylsilyl and tri-ethylsilyl, trimethylsilyl halides, silylated ureas such as bis(trimethylsilyl)urea (BSU), and silylated amides such as bis(trimethylsilyl)acetamide (BSA). Of these, BSA is preferred.

In general, the addition of at least 1 molar equivalent of silylating agent to a formula II compound, in the presence of an inert organic solvent, is sufficient to drive the step (a) reaction. However, it is advisable to use at least 2 molar equivalents of silylating agent per mole of substrate to optimize the silylation of formula II compounds. Suitable solvents for this reaction are tetrahydrofuran (THF) and, especially, dimethylformamide (DMF). It is preferable to operate step (a) of this process at a temperature in a range from about 25°C to about 60°C. However, the optimum operating temperature for a given reaction is easily found according to the routine skill of organic chemists.

When bis(trimethylsilyl)acetamide is employed as the silylating agent, the reaction product is presumably a pyrrolo[2,3-d]pyrimidine of the formula

\[
\text{III}
\]

wherein R is as defined above.

Compounds of formula I are then formed by brominating, chlorinating or iodinating the reaction product from step (a). Ideally, step (b) is carried out in the same vessel immediately following the completion of step (a), and the mixture is allowed to cool to ambient temperature.

Bromination, chlorination and iodination of a reaction product from step (a) is accomplished through methods known by one of ordinary skill in the art. For example, the addition of N-chlorosuccinimide to the mixture of a formula II compound, a silylating agent and an inert organic solvent, results in the conversion of the formula II compound to a C-5 chlorinated compound of formula I.

Similarly, bromination of a formula II compound at the C-5 position is accomplished via the addition of known brominating agents such as elemental bromine, N-bromo-acetamide and N-bromosuccinimide. Of these, the use of N-bromosuccinimide is preferred.

Likewise, iodination of a formula II compound at the C-5 position is accomplished by the addition of known iodinating agents such as elemental iodine, iodine monochloride and N-iodosuccinimide. Of these, N-iodosuccinimide is preferred.

Depending upon the desired result, the selected halogenating agent should be added to the mixture in the amount of at least one molar equivalent per mole of substrate.

Step (b) of the process is preferably operated in the absence of light.

The necessary reaction time, for steps (a) and (b), is a function of the starting materials and the operating temperature. The optimum reaction time for a given process is, as always, a compromise which is found by considering the competing goals of throughput, which is favored by short reaction times, and maximum yield, which is favored by long reaction times.

Formula I compounds obtained from the product of this invention are readily isolated by pouring the mixture into water. The product is recovered according to ordinary procedures. For example, the product is collected by filtration, washed with water, dried, reslurried in an organic solvent such as methanol in chloroform, refiltered and redried. The recovered 4-hydroxy-5-halopyrrolo[2,3-d]pyrimidine usually does not need to be further purified for use as an intermediate.

Compounds of formula I are preferably useful as intermediates for preparing novel or known 4-hydroxy-pyrrolo
[2,3-d]pyrimidine-L-glutamic acid derivatives, or for preparing other intermediates which are useful for synthesizing such L-glutamic acid derivatives.

This use of formula I compounds is known in the art. For example, formula I compounds wherein R is hydrogen or alkyl of 1 to 4 carbon atoms are used to prepare N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives which are useful intermediates or final compounds (Taylor, U.S. pat. No. 4,996,206). Formula I compounds may also be useful for the preparation of pyrrolo[2,3-d]pyrimidine derivatives taught by Akimoto in U.S. Pat. Nos. 4,997,838 and 5,106,974. However, the use of formula I compounds prepared via the processes of this invention are not limited by these examples of such uses.

The following examples further illustrate the processes according to the present invention. The examples are not intended to be limiting to the scope of the invention, in any respect, and should not be so construed.

**Example 1**

2-Amino-4-hydroxypyrrolo[2,3-d]pyrimidine

A mixture of 136.7 g of bromoacetaldehyde diethylacetal, 347 mL of water, and 17.3 mL of concentrated HCl was heated to about 90°C with vigorous stirring for about 30 minutes, at which time a clear solution was obtained. The solution was cooled to room temperature and 68.3 g of NaOAc was added. The resulting solution was added, with stirring, to a suspension of 100 g of 2,4-diamino-6-hydroxypyrimidine and 34.2 g of NaOAc in 739 mL of water, which had been heated to 70-85°C. The reaction was allowed to proceed for 2 hours at 70-85°C, at which time the reaction was complete. The mixture was cooled to 0°C and held for about 1.5 hours. The mixture was then filtered and the collected product was washed with 500 mL of water and 500 mL of acetone, and dried, affording 72.3 g (79%) of 2-amino-4-hydroxypyrrolo[2,3-d]pyrimidine. A small sample was further purified by slurry in hot methanol, filtration, and drying, mp > 300°C. 1H NMR (300 MHz, DMSO-d6) δ 6.03 (s, 2 H), 6.13 (m, 1 H), 6.56 (dd, J = 3.3, 2.3 Hz, 1 H), 10.23 (bs, 1 H), 10.93 (bs, 1 H).

**Example 2**

2-(2,2-Dimethylpropionyl)amino-4-hydroxypyrrolo[2,3-d]pyrimidine

50 g of the 2-amino-4-hydroxypyrrolo[2,3-d]-pyrimidine obtained from Example 1 was suspended in 225 mL of toluene, and the toluene was distilled until no further water separated. To the mixture was added 182.8 g of pivalic anhydride and 1.82 g of 4-dimethylaminopyridine. The temperature was increased to 140-145°C, and residual toluene was removed by distillation. After about 8 hours, when the reaction was complete as indicated by HPLC analysis (acetonitrile - 1% aq. HOAc 3:7, C18 column, detection at 254 nm, flow rate 2.0 mL/min) the reaction mixture was cooled to room temperature. t-Butylmethyl ether (TBME) was then added to precipitate the product, and the mixture was slowly cooled to about -5°C and filtered. The wet cake was reslurried with TBME, filtered, and dried in vacuo at 45-50°C. The product thus obtained was slurried with IN HCl - DMF 9:1, filtered and dried, affording 45.7 g (65%) of 2-(2,2-dimethylpropionyl)amino-4-hydroxypyrrolo[2,3-d]pyrimidine, mp 296-301°C (dec). 1H NMR (300 MHz, DMSO-d6) δ 1.19 (s, 9 H), 6.36 (dd, J = 1.8, 3.2 Hz, 1 H), 6.91 (dd, J = 2.2, 3.2 Hz, 1 H), 10.76 (bs, 1 H), 11.54 (bs, 1 H).

**Example 3**

4-Hydroxy-5-bromopyrrolo[2,3-d]pyrimidine

To a solution of 1.0 g of 4-hydroxypyrrolo[2,3-d]pyrimidine in 20 ml of DMF, 3.8 g (2.5 eq) of bis(trimethylsilyl) acetamide was added, and the resulting solution was stirred at 40°C in an oil bath for about two hours. Completeness of silylation was indicated by NMR analysis of an aliquot showing disappearance of the N-3 proton signal. The reaction was cooled to ambient temperature and 1.6 g (1.2 eq) of N-bromosuccinimide (NBS), was added in one portion. The reaction mixture was protected from light and stirred at ambient temperature until completion was indicated by NMR analysis (disappearance of pyrrole C-H doublets and emergence of a single, finely split doublet at δ 7.16, about 2 h). The mixture was poured into 50 mL of water, with stirring. After 1-2 hours, the product was collected by filtration, washed with water, dried, and reslurried in 10 volumes of 10% methanol in chloroform. Filtration and drying gave 1.2 g of 4-hydroxy-5-bromopyrrolo[2,3-d]pyrimidine (75% yield), mp 269-271°C (dec). 1H NMR (300 MHz, DMSO-d6) δ 1.19 (s, 9 H), 6.36 (dd, J = 1.8, 3.2 Hz, 1 H), 6.91 (dd, J = 2.2, 3.2 Hz, 1 H), 10.76 (bs, 1 H), 11.54 (bs, 1 H).
Example 4

2-Methyl-4-hydroxy-5-bromopyrrolo[2,3-d]pyrimidine

[0039] Yield of the title compound was 84%, mp 300-305°C (dec). 1H NMR (300 MHz, DMSO-d6) δ 2.23 (s, 3 H), 7.07 (d, J = 2.1 Hz, 1 H), 11.77 (s, 1 H), 11.91 (s, 1 H). 13C NMR (75.5 MHz, DMSO-d6) δ 20.8, 89.1, 103.2, 119.6, 148.1, 153.5, 158.2. HRMS m/z (M+) calcd for C7H6BrN3O: 227.9773. Found: 227.9789.

Example 5

2-(2,2-Dimethylpropionyl)amino-4-hydroxy-5-bromopyrrolo[2,3-d]pyrimidine

[0040] Yield of the title compound was 59%, mp 277-281°C (dec). 1H NMR (300 MHz, DMSO-d6) δ 1.18 (s, 9 H), 7.09 (d, J = 2.5 Hz, 1 H), 10.82 (s, 1 H), 11.82 (s, 1 H), 11.87 (s, 1 H). 13C NMR (75.5 MHz, DMSO-d6) δ 26.3, 39.7, 89.5, 101.9, 119.6, 147.1, 147.3, 156.0, 180.9. Anal. Calcd for C11H13BrN4O2: C, 42.19; H, 4.18; N, 17.89. Found: C, 41.77; H, 4.10; N, 17.58.

Example 6

dimethyl N-[4-(4-hydroxypyrrolo[2,3-d]pyridin-5-ylyethynyl)benzoyl-L-glutamate

[0041] To mixture of 10 mmol of 4-hydroxy-5-iodopyrrolo[2,3-d]pyrimidine in 40 mL of dimethylformamide is added 4.0 g of dimethyl N-(4-ethynylbenzoyl)-L-glutamate, 0.38 g of copper(I) iodide, 3 mL of triethylamine, and 1.0 g of tetrakis(triphenylphosphine) palladium. This mixture is stirred at ambient temperature for two hours and poured into 500 mL of water. The solid is collected by filtration, air dried, and reflexed in 200 mL of methanol. The mixture is cooled and the solid collected by filtration and dissolved in 2 L of 10% methanol in methylene chloride, giving the title compound.

Example 7

N-{4-[2-(4-hydroxypyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamate

[0042] A mixture of 1.1 g of dimethyl N-[4-(4-hydroxypyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamate in 100 mL of 50% methanol in methylene chloride is hydrogenated at 50 psi for 24 h, filtered, and concentrated under reduced pressure. Ether is added to the residue and the solid is collected by filtration and dried to yield the title compound.

Claims

1. A process for preparing a 4-hydroxy-5-halopyrrolo[2,3-d]pyrimidine of the formula

\[
\begin{align*}
\text{OH} & \\
N & \\
N & \\
N & \\
N & \\
X & \\
\end{align*}
\]

wherein

- R is H, C1-C4 alkyl, C1-C4 alkoxy, benzyl, an aryl substituent which is unsubstituted or substituted and selected from phenyl, thiophenyl, pyridyl or furyl, or a substituent of the formula R1-NH-;
- R1 is an amino protecting group; and
- X is bromo, chloro or iodo, which comprises

(a) reacting a silylating agent with a 4-hydroxypyrrolo[2,3-d]pyrimidine of the formula
2. The process of Claim 1 wherein

R is H, methyl or R1-NH-; and
R1 is unsubstituted or substituted alkanoyl.

3. The process of Claim 2 wherein R1 is 2,2-dimethylpropionyl.

4. The process of Claim 2 wherein said silylating agent is bis(trimethylsilyl)acetamide.

5. The process of Claim 2 wherein said iodinating is accomplished by using N-iodosuccinimide.

6. The process of Claim 2 wherein said brominating is accomplished by using N-bromosuccinimide.

7. The process of Claim 4 wherein said iodinating is accomplished by using N-iodosuccinimide.

8. The process of Claim 4 wherein said brominating is accomplished by using N-bromosuccinimide.

9. The process of Claim 1 wherein steps a) and b) are carried out in the same vessel.

10. A process for preparing a compound of the formula

wherein

R is H, C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, aryl, benzyl, or a substituent of the formula R1-NH-;
R1 is an amino protecting group; and
the configuration about the carbon atom designated * is L;
or a salt thereof, which comprises

(a) reacting a silylating agent with a 4-hydroxypyrrrolo[2,3-d]pyrimidine of the formula
wherein R is as defined above, in the presence of an inert organic solvent;
(b) iodinating, brominating or chlorinating the reaction product from step (a);
(c) condensing the reaction product from step b, a compound of the formula

wherein

R and R\(^1\) are as defined above; and
X is bromo, chloro or iodo, with a compound of the formula

wherein R\(^2\) is the same or different carboxy protecting group;
(d) hydrogenating the reaction product from step c), a compound of the formula

wherein R, R\(^1\), R\(^2\) and * are as defined above; and
(e) optionally converting the reaction product from step d) into a pharmaceutically acceptable salt.
Patentansprüche

1. Verfahren zur Herstellung eines 4-Hydroxy-5-halogenpyrrolo[2,3-d]pyrimidins der Formel

\[
\begin{align*}
\text{OH} & \\
\text{N} & \\
\text{R} & \\
\text{N} & \\
\text{X} & \\
\end{align*}
\]

worin

R steht für H, C₁₋₄ Alkyl, C₁₋₄ Alkoxy, Benzyl, einen Arylsubstituenten, der unsubstituiert oder substituiert ist und ausgewählt ist aus Phenyl, Thiophenyl, Pyridyl oder Furanyl, oder einen Substituenten der Formel R¹-NH⁻, worin

R¹ für eine Aminoschutzgruppe steht und

X für Brom, Chlor oder Iod steht, gekennzeichnet durch

(a) Umsetzung eines Silylierungsmittels mit einem 4-Hydroxy-pyrrolo[2,3-d]pyrimidin der Formel

\[
\begin{align*}
\text{OH} & \\
\text{N} & \\
\text{R} & \\
\text{N} & \\
\end{align*}
\]

worin R wie oben definiert ist, in Gegenwart eines inerten organischen Lösemittels, und

(b) Iodierung, Bromierung oder Chlorierung des Reaktionsprodukts von Schritt (a).

2. Verfahren nach Anspruch 1, worin

R für H, Methyl oder R¹-NH⁻ steht, und

R¹ für unsubstituiertes oder substituiertes Alkanoyl steht.

3. Verfahren nach Anspruch 2, worin R¹ für 2,2-Dimethylpropionyl steht.

4. Verfahren nach Anspruch 2, worin das Silylierungsmittel Bis(trimethylsilyl)acetamid ist.

5. Verfahren nach Anspruch 2, worin die Iodierung mittels N-Iodsuccinimid erreicht wird.

6. Verfahren nach Anspruch 2, worin die Bromierung mittels N-Bromsuccinimid erreicht wird.

7. Verfahren nach Anspruch 4, worin die Iodierung mittels N-Iodsuccinimid erreicht wird.

8. Verfahren nach Anspruch 4, worin die Bromierung mittels N-Bromsuccinimid erreicht wird.

9. Verfahren nach Anspruch 1, worin die Schritte (a) und (b) im gleichen Gefäß ausgeführt werden.

10. Verfahren zur Herstellung einer Verbindung der Formel
worin

R steht für H, C₁-C₄ Alkyl, C₁-C₄ Alkoxy, Aryl, Benzyl oder einen Substituenten der Formel R¹-NH⁻, worin R¹ für eine Aminoschutzgruppe steht und
die Konfiguration am mit * gekennzeichneten Kohlenstoffatom L ist,
or eines Salzes hiervon, gekennzeichnet durch

(a) Umsetzung eines Silylierungsmittels mit einem 4-Hydroxypyrrolo[2,3-d]pyrimidin der Formel

(b) Iodierung, Bromierung oder Chlorierung des Reaktionsprodukts von Schritt (a).

(c) Kondensierung des Reaktionsprodukts aus Schritt (b), nämlich einer Verbindung der Formel

worin R und R¹ wie oben definiert sind, und

X für Brom, Chlor oder Iod steht, mit einer Verbindung der Formel

 worin R² für die gleiche oder eine unterschiedliche Carboxyschutzgruppe steht,

(d) Hydrierung des Reaktionsprodukts von Schritt (c), nämlich einer Verbindung der Formel
Revendications

1. Procédé de préparation d'une 4-hydroxy-5-halogéno-pyrrolo-[2,3-d]pyrimidine répondant à la formule

\[
\text{R représente un atome d'hydrogène, un groupe alkyle en C}_1\text{-C}_4\text{, un groupe alcoxy en C}_1\text{-C}_4\text{, un groupe benzyle, un substituant aryle qui est substitué ou non-substitué et choisi parmi un groupe phényle, un groupe thiényle, un groupe pyridyle ou un groupe furyle, ou un substituant répondant à la formule R}^1\text{-NH-;}\]

\[
\text{R}^1\text{ représente un groupe amino-protecteur ; et}
\]

\[
\text{X représente un atome de brome, un atome de chlore ou un atome d'iode, qui comprend}
\]

(a) la réaction d'un agent de silylation avec une 4-hydroxy-pyrrolo-[2,3-d]pyrimidine répondant à la formule

\[
\text{R est tel que défini ci-dessus, en présence d'un solvant organique inerte ; et}
\]

(b) l'iodation, la bromation ou la chloration du produit de réaction provenant de l'étape (a).

2. Procédé selon la revendication 1, dans lequel

\[
\text{R représente un atome d'hydrogène, un groupe méthyle ou un groupe R}^1\text{-NH-;}\]

\[
\text{et}
\]

\[
\text{R}^1\text{ représente un groupe alcanoyl non-substitué ou substitué.}
\]

3. Procédé selon la revendication 2, dans lequel R\(^1\) représente un groupe 2,2-diméthylpropionyle.
Procédé selon la revendication 2, dans lequel ledit agent de silylation est le bis(triméthylsilyl)acétamide.

Procédé selon la revendication 2, dans lequel ladite iodation est accomplie en utilisant du N-iodosuccinimide.

Procédé selon la revendication 2, dans lequel ladite bromation est accomplie en utilisant du N-bromosuccinimide.

Procédé selon la revendication 4, dans lequel ladite iodation est accomplie en utilisant du N-iodosuccinimide.

Procédé selon la revendication 4, dans lequel ladite bromation est accomplie en utilisant du N-bromosuccinimide.

Procédé selon la revendication 1, dans lequel les étapes a) et b) sont effectuées dans le même récipient.

Procédé de préparation d'un composé répondant à la formule

\[
\text{RS}_{\text{NH}}\text{CONHCHCH}_{2}\text{CH}_{2}\text{COOH}
\]

\[
\text{R}
\]

R représente un atome d'hydrogène, un groupe alkyle en C\textsubscript{1}\textendash C\textsubscript{4}, un groupe alcoxy en C\textsubscript{1}\textendash C\textsubscript{4}, un groupe aryle, un groupe benzyle, ou un substituant répondant à la formule R\textsubscript{1}\textendash NH\textsuperscript{−} ;

R\textsubscript{1} représente un groupe amino-protecteur ; et

da la configuration pour l'atome de carbone désigné par * est L ;

ou un sel de celui-ci, qui comprend

(a) la réaction d'un agent de silylation avec une 4-hydroxypyrrolo-[2,3-d]pyrimidine répondant à la formule

\[
\text{R}_{\text{H}}\text{N}_{\text{NH}}\text{CONHCHCH}_{2}\text{CH}_{2}\text{COOH}
\]

\[
\text{R}
\]

dans laquelle R est tel que défini ci-dessus, en présence d'un solvant organique inerte ;

(b) l'iodation, la bromation ou la chloration du produit de réaction provenant de l'étape (a) ;

(c) la condensation du produit de réaction provenant de l'étape b, un composé répondant à la formule
dans laquelle

R et R\(^1\) sont tels que définis ci-dessus ; et

X représente un atome de brome, un atome de chloro ou un atome d'iode, avec un composé répondant à la formule

![Molécule 1](image1.png)

dans laquelle R\(^2\) représentent des groupes carboxy-protecteurs identiques ou différents ;

(d) l'hydrogénation du produit de réaction provenant de l'étape c), un composé répondant à la formule

![Molécule 2](image2.png)

dans laquelle R, R\(^1\), R\(^2\) et * sont tels que définis ci-dessus ; et

(e) la conversion facultative du produit de réaction provenant de l'étape d) en sel pharmaceutiquement acceptable.